Blepharitis - Pipeline Review, H2 2020
Blepharitis - Pipeline Review, H2 2020
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Blepharitis - Pipeline Review, H2 2020, provides an overview of the Blepharitis (Ophthalmology) pipeline landscape.
Blepharitis is an inflammation of the eyelids, usually caused by an excess growth of bacteria that is ordinarily found on the skin, blockage of the eyelid's oil glands, and occasionally allergies. Blepharitis signs and symptoms include watery eyes, red eyes, itchy eyelids, sensitivity to light. Treatment includes antibiotics, lubricating eye drops and steroid eye drops or ointments.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Blepharitis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Blepharitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Blepharitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Blepharitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 1 and 7 respectively.
Blepharitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Blepharitis - Pipeline Review, H2 2020, provides an overview of the Blepharitis (Ophthalmology) pipeline landscape.
Blepharitis is an inflammation of the eyelids, usually caused by an excess growth of bacteria that is ordinarily found on the skin, blockage of the eyelid's oil glands, and occasionally allergies. Blepharitis signs and symptoms include watery eyes, red eyes, itchy eyelids, sensitivity to light. Treatment includes antibiotics, lubricating eye drops and steroid eye drops or ointments.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Blepharitis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Blepharitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Blepharitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Blepharitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 1 and 7 respectively.
Blepharitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Blepharitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Blepharitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Blepharitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Blepharitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Blepharitis (Ophthalmology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Blepharitis (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Blepharitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Blepharitis - Overview
Blepharitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Blepharitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Blepharitis - Companies Involved in Therapeutics Development
Aerie Pharmaceuticals Inc
AxeroVision Inc
Azura Ophthalmics Ltd
Formosa Pharmaceuticals Inc
Hovione FarmaCiencia SA
Merck & Co Inc
NicOx SA
Novaliq GmbH
Premark Pharma GmbH
Quorum Innovations LLC
Surface Pharmaceuticals Inc
Tarsus Pharmaceuticals Inc
Blepharitis - Drug Profiles
(doxycycline + omega 3 fatty acid) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APP-13002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AXR-270 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZRBL-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Blepharitis - Dormant Projects
Blepharitis - Product Development Milestones
Featured News & Press Releases
Jun 15, 2020: Tarsus Pharmaceuticals announces positive results of the mars study, a phase 2a study of the efficacy and safety of TP-03 to treat Demodex Blepharitis, at ARVO 2020 Virtual Meeting
Apr 08, 2020: Nicox outlines plans to progress NCX 4251 into phase 2b trial following positive meeting with FDA
Dec 19, 2019: Nicox’s NCX 4251 meets primary endpoint in phase 2 blepharitis trial and shows promising efficacy in dry eye disease
Sep 27, 2019: Nicox completes enrolment of NCX 4251 phase 2 trial with top-line results on track for Q4 2019
Mar 19, 2019: Nicox initiates phase 2 trial of NCX 4251 in Blepharitis
Mar 18, 2019: Nicox poster presentation at AGS 2019 Annual Meeting Discloses preclinical data for NCX 4251, a novel blepharitis therapy
Mar 12, 2019: Nicox announces presentations including drug candidate NCX 4251 at upcoming scientific conferences
Jan 29, 2019: Nicox announces U.S. FDA acceptance of Investigational New Drug Application for NCX 4251 phase 2 trial in Blepharitis
Jan 05, 2017: Nicox provides clinical and regulatory update for NCX 4251 in blepharitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Blepharitis - Overview
Blepharitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Blepharitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Blepharitis - Companies Involved in Therapeutics Development
Aerie Pharmaceuticals Inc
AxeroVision Inc
Azura Ophthalmics Ltd
Formosa Pharmaceuticals Inc
Hovione FarmaCiencia SA
Merck & Co Inc
NicOx SA
Novaliq GmbH
Premark Pharma GmbH
Quorum Innovations LLC
Surface Pharmaceuticals Inc
Tarsus Pharmaceuticals Inc
Blepharitis - Drug Profiles
(doxycycline + omega 3 fatty acid) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APP-13002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AXR-270 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZRBL-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Blepharitis - Dormant Projects
Blepharitis - Product Development Milestones
Featured News & Press Releases
Jun 15, 2020: Tarsus Pharmaceuticals announces positive results of the mars study, a phase 2a study of the efficacy and safety of TP-03 to treat Demodex Blepharitis, at ARVO 2020 Virtual Meeting
Apr 08, 2020: Nicox outlines plans to progress NCX 4251 into phase 2b trial following positive meeting with FDA
Dec 19, 2019: Nicox’s NCX 4251 meets primary endpoint in phase 2 blepharitis trial and shows promising efficacy in dry eye disease
Sep 27, 2019: Nicox completes enrolment of NCX 4251 phase 2 trial with top-line results on track for Q4 2019
Mar 19, 2019: Nicox initiates phase 2 trial of NCX 4251 in Blepharitis
Mar 18, 2019: Nicox poster presentation at AGS 2019 Annual Meeting Discloses preclinical data for NCX 4251, a novel blepharitis therapy
Mar 12, 2019: Nicox announces presentations including drug candidate NCX 4251 at upcoming scientific conferences
Jan 29, 2019: Nicox announces U.S. FDA acceptance of Investigational New Drug Application for NCX 4251 phase 2 trial in Blepharitis
Jan 05, 2017: Nicox provides clinical and regulatory update for NCX 4251 in blepharitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Blepharitis, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Blepharitis - Pipeline by Aerie Pharmaceuticals Inc, H2 2020
Blepharitis - Pipeline by AxeroVision Inc, H2 2020
Blepharitis - Pipeline by Azura Ophthalmics Ltd, H2 2020
Blepharitis - Pipeline by Formosa Pharmaceuticals Inc, H2 2020
Blepharitis - Pipeline by Hovione FarmaCiencia SA, H2 2020
Blepharitis - Pipeline by Merck & Co Inc, H2 2020
Blepharitis - Pipeline by NicOx SA, H2 2020
Blepharitis - Pipeline by Novaliq GmbH, H2 2020
Blepharitis - Pipeline by Premark Pharma GmbH, H2 2020
Blepharitis - Pipeline by Quorum Innovations LLC, H2 2020
Blepharitis - Pipeline by Surface Pharmaceuticals Inc, H2 2020
Blepharitis - Pipeline by Tarsus Pharmaceuticals Inc, H2 2020
Blepharitis - Dormant Projects, H2 2020
Number of Products under Development for Blepharitis, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Blepharitis - Pipeline by Aerie Pharmaceuticals Inc, H2 2020
Blepharitis - Pipeline by AxeroVision Inc, H2 2020
Blepharitis - Pipeline by Azura Ophthalmics Ltd, H2 2020
Blepharitis - Pipeline by Formosa Pharmaceuticals Inc, H2 2020
Blepharitis - Pipeline by Hovione FarmaCiencia SA, H2 2020
Blepharitis - Pipeline by Merck & Co Inc, H2 2020
Blepharitis - Pipeline by NicOx SA, H2 2020
Blepharitis - Pipeline by Novaliq GmbH, H2 2020
Blepharitis - Pipeline by Premark Pharma GmbH, H2 2020
Blepharitis - Pipeline by Quorum Innovations LLC, H2 2020
Blepharitis - Pipeline by Surface Pharmaceuticals Inc, H2 2020
Blepharitis - Pipeline by Tarsus Pharmaceuticals Inc, H2 2020
Blepharitis - Dormant Projects, H2 2020
LIST OF FIGURES
Number of Products under Development for Blepharitis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
COMPANIES MENTIONED
Aerie Pharmaceuticals Inc
AxeroVision Inc
Azura Ophthalmics Ltd
Formosa Pharmaceuticals Inc
Hovione FarmaCiencia SA
Merck & Co Inc
NicOx SA
Novaliq GmbH
Premark Pharma GmbH
Quorum Innovations LLC
Surface Pharmaceuticals Inc
Tarsus Pharmaceuticals Inc
Number of Products under Development for Blepharitis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
COMPANIES MENTIONED
Aerie Pharmaceuticals Inc
AxeroVision Inc
Azura Ophthalmics Ltd
Formosa Pharmaceuticals Inc
Hovione FarmaCiencia SA
Merck & Co Inc
NicOx SA
Novaliq GmbH
Premark Pharma GmbH
Quorum Innovations LLC
Surface Pharmaceuticals Inc
Tarsus Pharmaceuticals Inc
